Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Medley VEGF: Avelumab + Axitinib in NSCLC and Urothelial Cancer
NCT03472560Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2018
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of avelumab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), sponsored by Pfizer. Started May 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03472560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472560.